立即打开
白宫发声:叫停强生疫苗不影响整体接种进度

白宫发声:叫停强生疫苗不影响整体接种进度

PHIL WAHBA 2021年04月14日
美国人接种的疫苗中,只有5%是来自3月初才开始在美国推出的强生疫苗。

星期二,白宫表示,尽管美国卫生当局建议暂停强生疫苗的接种,但由于早前已经采取了其他措施,以确保另外两种疫苗能大量供应,全国的疫苗接种运动不会受到太大干扰。

当天早些时候,美国疾控中心(CDC)和食药安全监管局(FDA)表示,由于在美国有6例接种了强生疫苗的人出现罕见且严重的血栓症状,有关机构建议暂停这种疫苗的接种。该公司的股价也在早盘交易中下跌了近3%。

强生疫苗在欧洲的推广也被推迟了。在欧洲,阿斯利康的疫苗也出现类似的副作用。

美国的疫苗接种正在如火如荼地展开:据美国疾控中心的疫苗追踪数据显示,约36.4%的美国人已至少接种了一剂新冠疫苗,22.3%的人已接种完两剂。这意味着美国人一共已经接种了约1.9亿剂疫苗。

白宫称,这其中只有5%是来自3月初才开始在美国推出的强生疫苗,而那时,辉瑞和Moderna疫苗已经开始接种很久了。更重要的是,白宫的疫情协调员杰夫·齐恩茨(Jeff Zients)在一份声明中说,该国的辉瑞疫苗和Moderna疫苗供应量充足,即使叫停了强生,这两家的剂量也足够保障美国的“疫苗接种计划不会受到重大影响”。

齐恩茨补充说,由于拜登已确保有足够多的辉瑞和Moderna疫苗给3亿美国人接种,美国政府的库存“足以继续维持目前每天接种300万针的速度”。拜登的目标是在4月30日——他就职的第100天,全美实现2亿剂的注射量,从该国目前的状况来看,这很容易达到。

同时,强生的疫苗只需要注射一次,而不像辉瑞和Moderna的那样要注射两次,这就点燃了人们的希望,期盼着它能加快疫苗接种计划的进程。

尽管疾控中心和食药安全监管局的举措只是“建议”而不是“指令”,但某些地区还是叫停了强生疫苗。纽约市长比尔·德·布拉西奥(Bill de Blasio)本人就曾经接种过强生疫苗,但他表示,纽约市将立即停止该疫苗的供应,直到另行通知可以接种为止。西弗吉尼亚等州当局也将采取行动。纽约一名市议员说,任何原计划于今天在该州的集中接种地点打强生疫苗的人,都可以打到一剂辉瑞疫苗。

这样一来,美国各州,以及在疫苗接种中共同负责一些环节的单位,例如各个城市和药店,便会争相管控各自手中的疫苗剂量,以保证本来要打强生疫苗的人都能打上一剂辉瑞或Moderna疫苗,还要能保证他们在三四周后打上第二针。

与辉瑞和Moderna的疫苗不同,强生疫苗没有使用前两家公司的mRNA技术——该技术能让人体细胞产生一种激发免疫反应的蛋白质。而强生研发的是腺病毒载体疫苗,原理是将新冠病毒的遗传物质引入到另一种载体病毒中,使人的免疫系统学会识别并对抗新冠病毒。

这些医疗机构说,在美国有超过680万人接种了强生疫苗,但6人出现了严重的血栓状况,并补充说:“这些症状似乎极为罕见。”美国疾控中心和食药安全监管局都表示,任何接种了强生疫苗并在三周内出现严重头痛,腹痛,腿痛或呼吸急促症状的人,都应及时向医疗系统报告。

针对这些事件,美国疾控中心将在周三召开一次特别会议,以确定其严重性几何。(财富中文网)

编译:陈聪聪

星期二,白宫表示,尽管美国卫生当局建议暂停强生疫苗的接种,但由于早前已经采取了其他措施,以确保另外两种疫苗能大量供应,全国的疫苗接种运动不会受到太大干扰。

当天早些时候,美国疾控中心(CDC)和食药安全监管局(FDA)表示,由于在美国有6例接种了强生疫苗的人出现罕见且严重的血栓症状,有关机构建议暂停这种疫苗的接种。该公司的股价也在早盘交易中下跌了近3%。

强生疫苗在欧洲的推广也被推迟了。在欧洲,阿斯利康的疫苗也出现类似的副作用。

美国的疫苗接种正在如火如荼地展开:据美国疾控中心的疫苗追踪数据显示,约36.4%的美国人已至少接种了一剂新冠疫苗,22.3%的人已接种完两剂。这意味着美国人一共已经接种了约1.9亿剂疫苗。

白宫称,这其中只有5%是来自3月初才开始在美国推出的强生疫苗,而那时,辉瑞和Moderna疫苗已经开始接种很久了。更重要的是,白宫的疫情协调员杰夫·齐恩茨(Jeff Zients)在一份声明中说,该国的辉瑞疫苗和Moderna疫苗供应量充足,即使叫停了强生,这两家的剂量也足够保障美国的“疫苗接种计划不会受到重大影响”。

齐恩茨补充说,由于拜登已确保有足够多的辉瑞和Moderna疫苗给3亿美国人接种,美国政府的库存“足以继续维持目前每天接种300万针的速度”。拜登的目标是在4月30日——他就职的第100天,全美实现2亿剂的注射量,从该国目前的状况来看,这很容易达到。

同时,强生的疫苗只需要注射一次,而不像辉瑞和Moderna的那样要注射两次,这就点燃了人们的希望,期盼着它能加快疫苗接种计划的进程。

尽管疾控中心和食药安全监管局的举措只是“建议”而不是“指令”,但某些地区还是叫停了强生疫苗。纽约市长比尔·德·布拉西奥(Bill de Blasio)本人就曾经接种过强生疫苗,但他表示,纽约市将立即停止该疫苗的供应,直到另行通知可以接种为止。西弗吉尼亚等州当局也将采取行动。纽约一名市议员说,任何原计划于今天在该州的集中接种地点打强生疫苗的人,都可以打到一剂辉瑞疫苗。

这样一来,美国各州,以及在疫苗接种中共同负责一些环节的单位,例如各个城市和药店,便会争相管控各自手中的疫苗剂量,以保证本来要打强生疫苗的人都能打上一剂辉瑞或Moderna疫苗,还要能保证他们在三四周后打上第二针。

与辉瑞和Moderna的疫苗不同,强生疫苗没有使用前两家公司的mRNA技术——该技术能让人体细胞产生一种激发免疫反应的蛋白质。而强生研发的是腺病毒载体疫苗,原理是将新冠病毒的遗传物质引入到另一种载体病毒中,使人的免疫系统学会识别并对抗新冠病毒。

这些医疗机构说,在美国有超过680万人接种了强生疫苗,但6人出现了严重的血栓状况,并补充说:“这些症状似乎极为罕见。”美国疾控中心和食药安全监管局都表示,任何接种了强生疫苗并在三周内出现严重头痛,腹痛,腿痛或呼吸急促症状的人,都应及时向医疗系统报告。

针对这些事件,美国疾控中心将在周三召开一次特别会议,以确定其严重性几何。(财富中文网)

编译:陈聪聪

Despite the recommendation from U.S. health authorities to halt the use of the Johnson & Johnson/Janssen Pharmaceuticals vaccine, the national inoculation campaign will not be disrupted all that much thanks to earlier moves to secure a massive supply of two other vaccines, the White House said on Tuesday.

Earlier in the day, the Centers for Disease Control and Prevention and the Food and Drug Administration said that because of six U.S. cases of a rare and severe type of blood clotting in people who have gotten the J&J vaccine, the agencies are recommending that it stop being used for the time being. The company's shares were down nearly 3% in morning trading.

J&J is also delaying the rollout of its vaccine in Europe, where AstraZeneca's vaccine has been correlated with similar side effects.

The U.S. vaccine rollout has been humming along: According to the CDC's vaccination tracker, some 36.4% of Americans have received at least one shot of a COVID-19 vaccine, while 22.3% are fully inoculated. That translates to about 190 million doses having been administered to Americans.

But according to the White House, only 5% of those have been the J&J vaccine, which started being rolled out in the U.S. in early March, well after the Pfizer and Moderna shots did. What's more, the White House's COVID-19 response coordinator Jeff Zients said in a statement that the country had ample supply of Pfizer and Moderna—enough for the J&J pause not to have "a significant impact on our vaccination plan."

Zients added that because President Joe Biden had secured enough Pfizer and Moderna vaccines to inoculate 300 million Americans, the U.S. government's stock "is more than enough supply to continue the current pace of vaccinations of 3 million shots per day." Biden has set a goal of hitting 200 million shots by his 100th day in office, which is April 30, a target the country will easily surpass.

At the same time, J&J's vaccine requires one shot rather than the two being given for Pfizer and Moderna, which has spurred hope that its use would help to speed up the vaccination program.

While the CDC and FDA move is a recommendation, not a directive, some jurisdictions are already halting J&J vaccines. New York City Mayor Bill de Blasio, who himself got a J&J jab, said the city will immediately stop offering it until further notice, as have West Virginia authorities, among others. Anyone scheduled for a J&J shot at a New York State–run mass vaccination site today will get a Pfizer one instead, a city councilman said.

That will leave states and other partners such as cities and drugstores administering the vaccine scrambling to accommodate anyone set for a J&J vaccine to get one by Pfizer or Moderna, which also will require scheduling a second visit three or four weeks later.

In contrast to Pfizer’s and Moderna’s vaccines, the J&J vaccine does not use mRNA technology, which teaches cells to make a protein that spurs an immune response. Instead, it uses a viral vector method in which a different virus is introduced as coronavirus’s genetic material into the cells so that a person's immune system learns to recognize and fight the coronavirus.

More than 6.8 million people have received the J&J vaccine in the United States, but six have experienced the clot, the agencies said, adding that "these events appear to be extremely rare." The CDC and FDA said anyone who got the J&J vaccine and experienced symptoms including severe headache, abdominal pain, leg pain, or shortness of breath within the first three weeks should contact their health care provider.

The CDC will convene a special meeting on Wednesday to review the cases to determine how significant they are.

最新:
  • 热读文章
  • 热门视频
活动
扫码打开财富Plus App